Rallybio Corp (RLYB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.93+0.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RLYB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the merger with Avenzo Therapeutics to create a combined company focused on next-generation oncology therapies.
Newly stated in 2026-Q2. The merger agreement with Avenzo Therapeutics was announced with an expected closing in Q4 2026. This is a strategic growth priority with no prior quarters stating it. The transaction is pending and thus the trajectory is in progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Rallybio announced merger agreement with Avenzo Therapeutics, expected to close in Q4 2026.”
Continue efforts to control and reduce operating losses as part of financial discipline.
Stated as a priority in 7 of last 7 quarters. Operating losses have improved from -$11.61M in 2024-Q4 to -$5.65M in 2026-Q2, showing progress in managing operating expenses. The trajectory is delivering moderate improvement in operating income.
“Operating income was negative $5.65 million in 2026-Q2.”
“Operating income was negative $8.73 million in 2026-Q1.”
“Operating income was negative $6.41 million in 2025-Q4.”
“Operating income was negative $6.93 million in 2025-Q3.”
“Operating income was negative $10.06 million in 2025-Q2.”
“Operating income was negative $9.67 million in 2025-Q1.”
“Operating income was negative $11.61 million in 2024-Q4.”
Progress clinical development of RLYB116, a differentiated C5 inhibitor targeting complement dysregulation diseases.
Newly stated in 2026-Q2. The company continues clinical development of RLYB116 as its lead program targeting complement dysregulation diseases. No specific financial or clinical milestone data is provided in the current disclosures, so progress is qualitative and trajectory is ongoing.
“RLYB116 is a differentiated C5 inhibitor with potential to treat diseases of complement dysregulation.”
Over the trailing year it converted 0.79x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
17 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.